BELIMUMAB and MALAISE

Overview

MALAISE is the #9 most commonly reported adverse reaction for BELIMUMAB, manufactured by GlaxoSmithKline LLC. There are 1,393 FDA adverse event reports linking BELIMUMAB to MALAISE. This represents approximately 2.3% of all 60,128 adverse event reports for this drug.

Patients taking BELIMUMAB who experience malaise should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

MALAISE is a less commonly reported adverse event for BELIMUMAB, but still significant enough to appear in the safety profile.

Other Side Effects of BELIMUMAB

In addition to malaise, the following adverse reactions have been reported for BELIMUMAB:

• PRODUCT DOSE OMISSION ISSUE — 4,840 reports
• SYSTEMIC LUPUS ERYTHEMATOSUS — 3,749 reports
• FATIGUE — 2,005 reports
• DRUG INEFFECTIVE — 1,796 reports
• PAIN — 1,720 reports
• HEADACHE — 1,525 reports
• NAUSEA — 1,456 reports
• WRONG TECHNIQUE IN DEVICE USAGE PROCESS — 1,427 reports
• ARTHRALGIA — 1,332 reports
• INJECTION SITE PAIN — 1,318 reports

Other Drugs Associated with MALAISE

The following drugs have also been linked to malaise in FDA adverse event reports:

Does BELIMUMAB cause MALAISE?

MALAISE has been reported as an adverse event in 1,393 FDA reports for BELIMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is MALAISE with BELIMUMAB?

MALAISE accounts for approximately 2.3% of all adverse event reports for BELIMUMAB, making it a notable side effect.

What should I do if I experience MALAISE while taking BELIMUMAB?

If you experience malaise while taking BELIMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages